New York Senate Bill S07297

New York 2025-2026 Regular Session

• Introduced: 4/9/25
• Refer: 4/9/25

Caption

Relates to utilization review program standards; requires use of evidence-based and peer reviewed clinical review criteria; relates to prescription drug formulary changes and pre-authorization for certain health care services.

Impact

If enacted, S07297 would significantly alter the existing landscape of health care regulations relating to how utilization reviews are conducted, ensuring that insurance providers assess the necessity and appropriateness of healthcare services based on established scientific standards. The bill would create a standardized framework for pre-authorization, which could lead to faster decisions and clearer communications regarding coverage for patients. Such changes are designed to improve patient experience by minimizing delays and uncertainties associated with pre-authorization processes.

Summary

Bill S07297 aims to amend the public health law and the insurance law concerning the standards of utilization review programs used in healthcare services. The bill emphasizes the importance of employing evidence-based and peer-reviewed clinical review criteria for making determinations concerning health care services that require pre-authorization. This legislative measure seeks to enhance transparency and efficiency in the pre-authorization process, mandating that notifications about such determinations be communicated promptly to both the insured individuals and their healthcare providers within a specified timeframe.

Contention

While there are many potential benefits of S07297, key points of contention remain around its implementation and the practicalities involved. Critics may raise concerns about how these new standards will be interpreted and enforced, particularly regarding the balance between insurer discretion and patient access to healthcare. Opponents might argue that while the intent is to enhance clinical appropriateness, the bill could inadvertently lead to stricter controls that could limit patient access to necessary treatments or create additional bureaucratic hurdles for healthcare providers.